Somatotropin Deficiency Pipeline Insight
DelveInsight’s, “Somatotropin Deficiency – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Somatotropin Deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Somatotropin Deficiency Understanding
Somatotropin Deficiency: Overview
Somatotropin also known as growth hormone is about 190 amino acid long and is synthesized and secreted by somatotroph cells present in anterior pituitary. Somatotropin plays a major role in certain complex physiological processes such as growth and metabolism. Inadequate secretion of somatotropin hormone can lead to growth hormone deficiency or Somatotropin Deficiency in humans. The disease can either be present from birth (congenital) due to genetic mutations or from structural defects in brain or else can be acquired in later stage of life owing to tumors in pituitary, radiations, central nervous system infections, or severe head injuries. Somatotropin Deficiency affects male and female population equally except for GHD III which only affects male population.
Symptoms can include slow growth or absent of growth, delay in development of facial bones, delayed lengthening of long bones, slow teeth eruption, decreased energy levels, increase in abdominal and visceral fat mass, and anxiety.
Diagnosing Somatotropin Deficiency can be done by evaluating the growth hormone level through blood test. However, lower than normal level is not enough evidence for diagnosis as growth hormone level widely fluctuate during day and night. Therefore, diagnosing Somatotropin Deficiency also requires assessments of growth plate development via X-rays, MRI scans to check for tumors in pituitary, any head injury, and genetic testing for determining genetic mutations.
Treatments for Somatotropin Deficiency currently include dosage of recombinant human growth hormone to optimize the growth potential. Initially, the dosage is gradually increased to its highest dose during puberty and is discontinued at completion of skeletal maturation. Later the patient may require retesting for further recombinant therapy. Some of the FDA approved drugs for the treatment of Somatotropin Deficiency includes Nutropin, Norditropin, Genotropin, and others..
The companies and academics are working to assess challenges and seek opportunities that could influence Somatotropin Deficiency R&D. The therapies under development are focused on novel approaches to treat/improve Somatotropin Deficiency.
Somatotropin Deficiency Emerging Drugs Chapters
This segment of the Somatotropin Deficiency report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Somatotropin Deficiency Emerging Drugs
Ethansomatropin (GX-H9): Genexine
Genexine’s drug candidate, Ethansomatropin (GX-H9), is a class of recombinant somatropin fusion protein molecule in phase III for the treatment of Somatotropin Deficiency. The drug stimulates the production of insulin-like growth factor-1 in the liver, which has growth-stimulating effects on various tissues and increases the activities of osteoclast, and chondrocytes tissues thus stimulating bone growth.
Ibutamoren (LUM-201): Lumos Pharma
Lumos Pharma’s “breakthrough” drug Ibutamoren (LUM-201) is currently being evaluated for the treatment of Somatotropin Deficiency and has demonstrated good safety and efficacy profile in phase II trials. Ibutamoren is an orphan drug and is a growth hormone releasing factor agonists.
Further product details are provided in the report……..
Somatotropin Deficiency: Therapeutic Assessment
This segment of the report provides insights about the different Somatotropin Deficiency drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Somatotropin Deficiency
There are approx. 10+ key companies which are developing the therapies for Somatotropin Deficiency. The companies which have their Somatotropin Deficiency drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Genexine and others.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Somatotropin Deficiency pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Somatotropin Deficiency: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Somatotropin Deficiency therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Somatotropin Deficiency drugs.
Somatotropin Deficiency Report Insights
- Somatotropin Deficiency Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Somatotropin Deficiency Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Somatotropin Deficiency drugs?
- How many Somatotropin Deficiency drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Somatotropin Deficiency?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Somatotropin Deficiency therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Somatotropin Deficiency and their status?
- What are the key designations that have been granted to the emerging drugs?